Dr. Vollmer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Academic Office 1 Building
12631 E. 17th Ave., Mail Stop B185
Aurora, CO 80045Phone+1 303-724-2187
Education & Training
Stanford Health Care-Sponsored Stanford UniversityChief Residency, Neurology, 1986 - 1987- Stanford Health Care-Sponsored Stanford UniversityPost-Doctoral Fellowship, Neuroimmunology & Multiple Sclerosis, 1985 - 1986
- Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 1983 - 1985
Yale-New Haven Medical CenterInternship, Internal Medicine, 1982 - 1983
Stanford University School of MedicineClass of 1982
University of WyomingBA, Zoology, Highest Honors, 1973 - 1977
Certifications & Licensure
CA State Medical License 1983 - Present
AZ State Medical License 2002 - 2027
CO State Medical License 1993 - 2025
WY State Medical License 1994 - 2023
CT State Medical License 1987 - 2002
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.João J Cerqueira, Achim Berthele, Bruce A C Cree, Massimo Filippi, Gabriel Pardo
Neurology. 2025-02-25 - Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.Hans-Peter Hartung, Ralph H B Benedict, Thomas Berger, Robert A Bermel, Bruno Brochet
Neurology. 2024-12-24 - ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.Hans-Peter Hartung, Thomas Berger, Robert A Bermel, Bruno Brochet, William M Carroll
Journal of Neurology. 2024-07-01
Press Mentions
- News from the AAN Annual Meeting: When to Begin Aggressive Treatments in Patients with Multiple Sclerosis: It's a Matter of DebateJune 23rd, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
